Leukemia drug TGRX-678 gets a body scan: tiny study tracks its journey
NCT ID NCT06986772
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 study gave 6 healthy Chinese men a single dose of the leukemia drug TGRX-678 to see how the body absorbs, breaks down, and gets rid of it. Researchers measured radioactivity in blood, urine, and stool to map the drug's path. No treatment was given—just understanding how the drug behaves.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TGRX-678 (a tyrosine kinase inhibitor for chronic myeloid leukemia)
What this could lead to
If successful, this study will help doctors understand how TGRX-678 moves through the body and how it is eliminated, which can guide future dosing and safety decisions.
What could go wrong
This is a very early, small study in just 6 healthy men, not patients. It is designed to measure drug processing, not to test effectiveness or safety for treating leukemia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China